Roche Presents Eight-Year P-III (APHINITY) Study of Perjeta (pertuzumab) for HER2-Positive Early Breast Cancer at ESMO 2022
- The P-III (APHINITY) study evaluating Perjeta + Herceptin & CT vs Herceptin & CT in 4804 patients with HER2+ early breast cancer
- The results showed the continued benefit when given post-surgery IV treatment at 8.4yrs. median follow-up, treatment effect continues to be observed regardless of HR status, fewer deaths were observed (7.0% vs 8.4%), OS data remain immature & statistical significance has not yet been reached
- In the overall study population/LN+ disease/ HR+/ HR- disease, reduction in risk of breast cancer recurrence or death (23%/28% with an absolute benefit of 4.9%/ 25%/18%). Patients remained disease-free (88.4% vs 85.8%) with an absolute benefit of 2.6% & the safety profile was consistent with prior studies with no new or unexpected safety signals
Ref: GlobalNewswire | Image: Roche
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.